Voyager Therapeutics (NASDAQ:VYGR) Shares Cross Below 50 Day Moving Average – What’s Next?

Voyager Therapeutics, Inc. (NASDAQ:VYGR)’s share price passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $3.83 and traded as low as $3.43. Voyager Therapeutics shares last traded at $3.50, with a volume of 540,804 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Truist Financial raised shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Wall Street Zen cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright reissued a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, May 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Voyager Therapeutics in a research note on Wednesday, April 15th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Voyager Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Voyager Therapeutics Stock Performance

The company’s 50 day moving average price is $3.83 and its 200-day moving average price is $3.94. The company has a market cap of $211.47 million, a price-to-earnings ratio of -1.78 and a beta of 1.25.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. The company had revenue of $1.19 million for the quarter, compared to analysts’ expectations of $8.79 million. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%. As a group, sell-side analysts forecast that Voyager Therapeutics, Inc. will post -1.66 earnings per share for the current year.

Insider Activity

In other news, CEO Alfred Sandrock sold 11,511 shares of Voyager Therapeutics stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $3.87, for a total value of $44,547.57. Following the transaction, the chief executive officer owned 472,549 shares of the company’s stock, valued at $1,828,764.63. The trade was a 2.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 12.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Hedge funds have recently made changes to their positions in the business. Chase Investment Counsel Corp acquired a new position in shares of Voyager Therapeutics in the first quarter worth about $76,000. Patriot Financial Group Insurance Agency LLC boosted its holdings in shares of Voyager Therapeutics by 100.3% in the first quarter. Patriot Financial Group Insurance Agency LLC now owns 205,732 shares of the company’s stock worth $794,000 after buying an additional 103,016 shares during the period. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Voyager Therapeutics by 42,410.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 15,729 shares of the company’s stock worth $62,000 after buying an additional 15,692 shares during the period. EcoR1 Capital LLC boosted its holdings in shares of Voyager Therapeutics by 497.2% in the fourth quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company’s stock worth $15,731,000 after buying an additional 3,332,544 shares during the period. Finally, Altshuler Shaham Ltd acquired a new position in shares of Voyager Therapeutics in the fourth quarter worth about $801,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.